The Alexandria Real Estate Equities-backed regenerative medicine developer floated at the bottom of its range while cutting the number of shares.

The UC Berkeley-founded gene therapy developer plans to use the IPO proceeds to advance treatments for Fabry disease, cystic fibrosis and ophthalmological diseases.

Harvard's genomic editing technology spinout has filed to raise up to $100m, adding to some $225m of venture funding in under three years.

Comcast NBCUniversal and Grace Beauty scored exits as Peloton Interactive floated at the top of its range to raise $1.16bn, getting a further $100m in a private placement.

Aprea Therapeutics, a Karolinska Institute spinout, is set to raise as much as $92m from an offering that would bank Karolinska Development a return of up to $8m.

Frequency Therapeutics, a regenerative medicine developer advancing MIT and Harvard research, has set the range for an initial public offering that will raise $107m if it floats at the high end.

Fosun-backed Shanghai Henlius Biotech has priced shares at the bottom of its range to raise $410m in its initial public offering ahead of public trading next week.

Haldor Topsøe remains the largest shareholder of cancer treatment developer IGM Biosciences, whose shares have risen more than 50% since it floated yesterday.

The developing digital health sector has had to wait almost three years for the public markets to open up to it, but when they did, it was corporate venturing portfolio companies that were first through the flotation exit doors.

Pfizer spinoff Springworks, which also counts GlaxoSmithKline as an investor, secured $162m in an initial public offering that followed $228m of funding.